Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (31-40 of 110) with videos related to

Pageof 11
Sort By:
Annals of Hepatology|February 12, 2013
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapyViola Knop, Gerlinde Teuber, Hartwig Klinker, et al.
Journal of Gastroenterology|September 14, 2011
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infectionViola Weich, Eva Herrmann, Tje Lin Chung, et al.
Hepatology Communications|June 6, 2022
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-RegistryFrank Tacke, Hartwig Klinker, Klaus H W Boeker, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 27, 2019
Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAsFrank Tacke, Klaus H W Boeker, Hartwig Klinker, et al.
European Journal of Gastroenterology & Hepatology|July 13, 2007
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trialBernd Kronenberger, Thomas Berg, Eva Herrmann, et al.
Brain Sciences|April 27, 2026
Health-Related Quality of Life in Previous Versus Current Opiate Users Receiving HCV Therapy: Registry-Based EvidenceMichael Specka, Stefan Christensen, Peter Buggisch, et al.
Zeitschrift Fur Gastroenterologie|May 15, 2019
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015Christoph Sarrazin, Peter Buggisch, Stefan Mauss, et al.
Hepatology (Baltimore, Md.)|May 30, 2003
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trialThomas Berg, Bernd Kronenberger, Holger Hinrichsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2018
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patientsBenjamin Maasoumy, Peter Buggisch, Stefan Mauss, et al.
United European Gastroenterology Journal|March 8, 2018
Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world settingChristoph Höner Zu Siederdissen, Peter Buggisch, Klaus Böker, et al.
Pageof 11

Showing results (31-40 of 110) with videos related to

Sort By:
Pageof 11
Annals of Hepatology|February 12, 2013
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapyViola Knop, Gerlinde Teuber, Hartwig Klinker, et al.
Journal of Gastroenterology|September 14, 2011
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infectionViola Weich, Eva Herrmann, Tje Lin Chung, et al.
Hepatology Communications|June 6, 2022
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-RegistryFrank Tacke, Hartwig Klinker, Klaus H W Boeker, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 27, 2019
Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAsFrank Tacke, Klaus H W Boeker, Hartwig Klinker, et al.
European Journal of Gastroenterology & Hepatology|July 13, 2007
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trialBernd Kronenberger, Thomas Berg, Eva Herrmann, et al.
Brain Sciences|April 27, 2026
Health-Related Quality of Life in Previous Versus Current Opiate Users Receiving HCV Therapy: Registry-Based EvidenceMichael Specka, Stefan Christensen, Peter Buggisch, et al.
Zeitschrift Fur Gastroenterologie|May 15, 2019
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015Christoph Sarrazin, Peter Buggisch, Stefan Mauss, et al.
Hepatology (Baltimore, Md.)|May 30, 2003
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trialThomas Berg, Bernd Kronenberger, Holger Hinrichsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2018
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patientsBenjamin Maasoumy, Peter Buggisch, Stefan Mauss, et al.
United European Gastroenterology Journal|March 8, 2018
Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world settingChristoph Höner Zu Siederdissen, Peter Buggisch, Klaus Böker, et al.
Pageof 11